Verona pharma announces us fda approval of ohtuvayre™ (ensifentrine)

Ohtuvayre is indicated for the maintenance treatment of copd allowing for broad use in copd patients first inhaled copd treatment providing bronchodilation and non-steroidal anti-inflammatory effects conference call tomorrow at 8:30 a.m. edt / 1:30 p.m.
VRNA Ratings Summary
VRNA Quant Ranking